Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | DRD5 | P21918 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 3/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113497 | 0.91 | HRH1 (0.67) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL8406223 | 0.84 | DRD2 (0.68) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL3296125 | 0.83 | DRD2 (0.68) | DRD2DRD1DRD4DRD5HTR1B | |
| Hydrochloric Acid SCHEMBL8699695 | 0.82 | DRD2 (0.66) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL7467550 | 0.82 | DRD2 (0.66) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL12408539 | 0.81 | KDM4E (0.52) | DRD2DRD1DRD4DRD5HTR1B | |
| SCHEMBL2911943 | 0.79 | MAPT (0.52) | DRD2DRD1KDM4ESMN1; SMN2 | |
| Phenyltoloxamine SCHEMBL5145512 | 0.79 | DRD1 (1.00) | DRD2DRD1DRD4DRD5HTR7 | |
| Phenyltoloxamine SCHEMBL28854 | 0.79 | DRD1 (1.00) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL10190893 | 0.79 | DRD2 (0.62) | DRD2DRD1DRD4DRD5HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3527569-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA FOR USE IN TREATING DRYE EYE | Vitae Pharmaceuticals, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3102576-B1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | DRD2 3314/4885DRD1 2776/4885DRD4 3416/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | DRD2 432/4885DRD1 329/4885DRD4 105/4885 |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | DRD2 3259/4885DRD1 2894/4885DRD4 3389/4885 |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | DRD2 3314/4885DRD1 2776/4885DRD4 3416/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | DRD2 432/4885DRD1 329/4885DRD4 105/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | DRD2 4664/4885DRD1 4682/4885DRD4 4350/4885 |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | DRD2 3314/4885DRD1 2776/4885DRD4 3416/4885 |
| US-20080146567-A1 | QUINOLINES | HTR5A, HTR2B, HTR2C | DRD2 33/4885DRD1 57/4885DRD4 82/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | DRD2 395/4885DRD1 327/4885DRD4 134/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | DRD2 3314/4885DRD1 2776/4885DRD4 3416/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | DRD2 147/4885DRD1 148/4885DRD4 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.